These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36171566)

  • 1. The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy.
    Votava M; Bartolini R; Capkova L; Smetanova J; Jiri V; Kuchar M; Kalfert D; Plzak J; Bartunkova J; Strizova Z
    BMC Cancer; 2022 Sep; 22(1):1021. PubMed ID: 36171566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the new angel better than the old devil? Challenges and opportunities in CD47- SIRPα-based cancer therapy.
    Olaoba OT; Ayinde KS; Lateef OM; Akintubosun MO; Lawal KA; Adelusi TI
    Crit Rev Oncol Hematol; 2023 Apr; 184():103939. PubMed ID: 36774991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment.
    Sakakura K; Takahashi H; Kaira K; Toyoda M; Murata T; Ohnishi H; Oyama T; Chikamatsu K
    Lab Invest; 2016 Sep; 96(9):994-1003. PubMed ID: 27322955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the regulation of "Don't Eat-Me" signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy.
    Karizak AZ; Salmasi Z; Gheibihayat SM; Asadi M; Ghasemi Y; Tajbakhsh A; Savardashtaki A
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):511-529. PubMed ID: 36342520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
    Theruvath J; Menard M; Smith BAH; Linde MH; Coles GL; Dalton GN; Wu W; Kiru L; Delaidelli A; Sotillo E; Silberstein JL; Geraghty AC; Banuelos A; Radosevich MT; Dhingra S; Heitzeneder S; Tousley A; Lattin J; Xu P; Huang J; Nasholm N; He A; Kuo TC; Sangalang ERB; Pons J; Barkal A; Brewer RE; Marjon KD; Vilches-Moure JG; Marshall PL; Fernandes R; Monje M; Cochran JR; Sorensen PH; Daldrup-Link HE; Weissman IL; Sage J; Majeti R; Bertozzi CR; Weiss WA; Mackall CL; Majzner RG
    Nat Med; 2022 Feb; 28(2):333-344. PubMed ID: 35027753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
    Tong B; Wang M
    Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 8. Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade.
    Anderson KL; Snyder KM; Ito D; Lins DC; Mills LJ; Weiskopf K; Ring NG; Ring AM; Shimizu Y; Mescher MF; Weissman IL; Modiano JF
    Melanoma Res; 2020 Apr; 30(2):147-158. PubMed ID: 31205227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tumor cell-to-macrophage communication by blocking Vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis.
    Zhang C; Liu Y; Jiang J; Chen C; Duan Z; Su H; Wang S; Tian B; Shi Y; Xiang R; Luo Y
    Theranostics; 2024; 14(7):2757-2776. PubMed ID: 38773982
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer.
    Wang Q; Feng C; Chen Y; Peng T; Li Y; Wu K; Pu X; Chen H; Liu J
    J Immunol Res; 2023; 2023():2473075. PubMed ID: 37719086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
    Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
    J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response.
    Strizova Z; Kuchar M; Capkova L; Komarc M; Skrivan J; Bartunkova J; Plzak J; Smrz D
    Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33917866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal.
    Li C; Liu Y; Li D; Wang Q; Zhou S; Zhang H; Wang Y; He Z; Liu H; Sun J
    Theranostics; 2022; 12(10):4581-4598. PubMed ID: 35832081
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
    Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
    Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-Mediated CD47-SIRPα Blockade and Calreticulin Exposure for Improved Cancer Chemo-Immunotherapy.
    Luo JQ; Liu R; Chen FM; Zhang JY; Zheng SJ; Shao D; Du JZ
    ACS Nano; 2023 May; 17(10):8966-8979. PubMed ID: 37133900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated Analysis of Phagocytic and Immunomodulatory Markers in Cervical Cancer Reveals Constellations of Potential Prognostic Relevance.
    Yordanov A; Damyanova P; Vasileva-Slaveva M; Hasan I; Kostov S; Shivarov V
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay.
    Kuchar M; Strizova Z; Capkova L; Komarc M; Skrivan J; Bartunkova J; Smrz D; Plzak J
    Biomedicines; 2021 Jan; 9(2):. PubMed ID: 33498270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
    Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
    Aroldi A; Mauri M; Ramazzotti D; Villa M; Malighetti F; Crippa V; Cocito F; Borella C; Bossi E; Steidl C; Scollo C; Voena C; Chiarle R; Mologni L; Piazza R; Gambacorti-Passerini C
    J Cell Mol Med; 2023 Oct; 27(20):3053-3064. PubMed ID: 37654003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.